Long $NAUT. Recent de-SPAC backed by no other than AMAZON and JEFF BEZOS. Heavyweight investors include PERCEPTIVE & ORBIMED. Recent insider buying. Flush with $350 million cash. Son of $EFTR. $25 target.
— BiotechBreakthroughs (@BioBreakthrough) September 8, 2021